Using brain markers to test NPC-1 for Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have noticed mild memory problems, or have been diagnosed with mild cognitive impairment or early Alzheimer's dementia.
- You have a friend or family member who can help with study visits and report on your daily life.
- Your blood test or brain scan shows signs of Alzheimer's (like abnormal amyloid or tau proteins).
- You are generally healthy, with stable medications for at least 3 months.
- You have not had a major stroke, brain tumor, or seizure in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This Phase 3 study looks for blood/brain “biomarkers” linked to aging, memory changes, and early brain degeneration. It may help researchers better identify who is at risk and how biology relates to thinking and memory, using brain scans and thinking tests.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Hear when a new Subjective Cognitive Decline (SCD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.